Now more than ever, the publication of the annual report represents a key milestone in the journey of the European Society for Radiotherapy and Oncology (ESTRO). The year 2021 was crucial for us, as it presented us with the challenge of giving new momentum to our Society after the shock caused by the Covid-19 pandemic. The past two years have had a tremendous impact on the world’s economy and the health sector. In this uncertain context, it was vital that we ensured that ESTRO kept a pulse on the needs and expectations of our community. By building on the lessons learned in 2020 and by leveraging the opportunities offered by the digital environment, we were able to offer our community a rich and diverse portfolio of activities.

First of all, the ESTRO 2021 congress was very successful. The event took place in person in Madrid, with more than 2,300 participants on site and a full technical exhibition. On-site participation was complemented by a feature-rich online platform, which enabled an additional 1,700 participants to follow all talks in real time and asynchronously.

The success of ESTRO 2021 provided an excellent showcase of how ESTRO was able to turn the difficult context of the pandemic into an opportunity to bring forth new ideas and create value for our community. The same approach was adopted in courses, meetings and workshops, with positive results both in the assortment of the offers and the size of the engaged audience.

The previous year, 2020, had been complicated, with several repercussions on ESTRO’s financial outlook. While we are not out of the woods just yet, 2021 certainly marked a change of tide, which would not have been possible without the commitment of our staff and members. This sense of togetherness and community that came out at its strongest in this time of need is what gives meaning to our mission.

Without further ado, I would now like to bring to your attention some of the highlights of the year:

**Membership**

The membership base in 2021 experienced a decrease of roughly 5% from that of 2020, falling from 7,618 members to 7,229. Given the timeline for membership renewal, we expected 2021 to provide a more accurate indication of the impact of the pandemic than 2020. In this sense, the overall outlook in terms of membership figures remained stable and we can expect the trend to improve as of 2022. The institutional membership continued to be buoyant, as 50 centres across Europe used this scheme. At the same time, more national and international societies applied for joint membership agreements with ESTRO, and this trend is an important testimony of the trust we have managed to build with our members and international partners.

**Science & dissemination**

With over 4,000 registered participants, ESTRO 2021 was a good achievement for the Society. Despite the uncertainties
caused by Covid-19 restrictions, we were able to deliver a scientific event of the highest calibre both on site and online. ESTRO took a bold decision, and we were the first medical society that organised an on-site congress during the covid pandemic. For this achievement, I praise the efforts of our speakers on site and online and the scientific programme committee.

Our family of journals continues to grow steadily. *Radiotherapy & Oncology* obtained its highest impact factor in 2020, while *Clinical and Translational Radiation Oncology* and *Physics and Imaging in Radiation Oncology* are on track to receive impact factors shortly. *Technical Innovations and Patient Support in Radiation Oncology* performed exceptionally well in 2021 and is expected to meet the conditions to apply for an impact factor soon. Well done to the editorial boards. A detailed report on the performance of the journals is available in the science & dissemination section of the full report.

In 2021, the advisory committee on radiation oncology practice (ACROP) intensified its efforts to develop clinical and technical guidelines in the field of radiation oncology. We are currently restructuring ACROP to improve the streamlining of guideline development within ESTRO while also better positioning the Society and our discipline in joint multidisciplinary guideline efforts that involve other professional oncology societies both within and outside Europe. The list of guidelines that were developed or endorsed under the ACROP umbrella in 2021 is provided in the science & dissemination section.

Lastly, in that same section you can read more about the research projects in which ESTRO is currently engaged.

Education
Much like 2020, the 2021 calendar of the ESTRO school mostly comprised online courses. However, building on the experience of the previous year, the School was able to face this second year of the pandemic more effectively than the first: 23 teaching courses were rolled out in 2021 (as opposed to 10 in 2020), with almost 2,000 delegates involved. The courses were complemented by 14 contouring workshops, which were attended by over 400 professionals (this marks the best result yet in terms of the number of attendees). This year, the School made full use of the benefits offered by the online environment, and was able to implement a wide-ranging educational offer. Many courses involved both synchronous and asynchronous teaching, and in some cases live broadcasts could be organised with the faculties. Course programmes were also adapted and made more flexible, with some courses spreading over several weeks and others offering more condensed teaching. This increased flexibility enabled the School to expand its geographical scope to appeal to a large international audience.

There has been a strong focus this year on course formats, but the School as always has made it a priority to keep its content relevant and up to date. In this vein, the update of the core curriculum for medical-physics experts in radiotherapy is welcome. It came to fruition after two years of intense work.

Partnerships
During 2021, ESTRO kept strengthening its interactions with many oncology and radiotherapy societies worldwide, as it signed and renewed a large number of memoranda of understanding with national and international societies. The ESTRO Cancer Foundation continued its work to address challenges in the uptake of radiotherapy by implementing successfully the UpLung and value-based healthcare projects.

In conclusion, I thank the whole of the ESTRO community for its continuous commitment and support, which made the achievements of our Society possible. I also acknowledge the input provided by non-members and all radiation oncology professionals who participated in the community survey and thereby gave precious insight into the needs and expectations of the radiation oncology
community with respect to the activities organised by the Society.

I must congratulate the Board, the councils and the committees, for using this time of crisis as an opportunity to increase communication, alignment and transparency. The Open Board, which now provides an annual forum at which all the governance bodies can meet and discuss, is the most visible outcome of this spirit of cooperation. I also welcome the reignition of the governance review, which had come to a halt in 2020 and is now being carried out with the involvement of all our governance bodies.

I thank the faculties of the ESTRO school for their flexibility in adapting their courses to the online environment, thus enabling the Society to maintain a manifold educational offer. A warm thank-you should also go to our corporate partners, which supported a highly successful technical exhibition during ESTRO 2021, and for the commitment they have already shown to ESTRO 2022. Finally, I give a heartfelt thank-you to the ESTRO staff, who helped us to embrace this disruptive year with resilience and perseverance.

The year of 2021 marked the beginning of our recovery and opens new opportunities to strengthen our community and work together towards our Vision 2030 goal. We will achieve this goal together, just like we managed to come together to face the challenge of the pandemic. Thank you all for helping ESTRO to advance our profession.

Prof Ben Slotman
ESTRO President
Mission

The mission of ESTRO, a non-profit, scientific organisation, shall be to foster, in all its aspects, radiotherapy (also known as radiation oncology), clinical oncology and related subjects, including physics as applied to radiotherapy, radiation technology and radiobiology.

To fulfil its mission ESTRO will:

- Develop and promote standards of education in radiotherapy and clinical oncology
- Promote standards of practice in radiotherapy, clinical oncology and related subjects
- Stimulate the exchange of scientific knowledge in all related fields
- Strengthen the clinical specialty of radiotherapy and clinical oncology in relation to other specialties and professions involved in cancer management
- Encourage co-operation with international, regional and national societies and bodies representing radiotherapy, clinical oncology and related subjects
- Facilitate research and development in radiotherapy, clinical oncology and related subject.
ESTRO has a long track record of organising conferences, disseminating the latest findings and providing a platform for networking thus working towards an optimal treatment care for cancer patients.
A new hybrid format
For the first time, the ESTRO annual congress could offer its delegates two formats: onsite in Madrid or online. With a global context still unsure due to the Covid-19 pandemic, the hybrid format was the most appropriate solution to enable maximum access to the great science presented and even to interact and network.

ESTRO 2021, a first mover
ESTRO has been the first medical society to organise a medical congress welcoming participants onsite right after the major pandemic spikes, as soon the healthcare context allowed large scale gatherings.

A feature-rich online platform
Not only were delegates able to access all the congress’ content onsite and online, but they were also provided with a tool to follow parallel sessions that they would have otherwise not been able to follow in a purely onsite context.

A top-level scientific programme
ESTRO 2021 showcased the latest advances in Radiation Oncology through plenary award lectures, symposia, debates, proffered papers highlighting results of clinical trials and late-breaking abstracts.

An opportunity to learn from experts
ESTRO 2021 offered a diversified educational programme of interest to all the disciplines of Radiation Oncology through pre-meeting courses, teaching lectures and contouring sessions. The educational programme of the congress is discussed in the school section of this report.
### Participation

4,120 Delegates

- **2,372 Onsite Delegates**
  - 82% Participants
  - 18% Company delegates

- **1,748 Online Delegates**
  - 90% Participants
  - 10% Company delegates

#### Breakdown per Specialty

- **46% Radiation Oncologists**
  - Onsite: 52%
  - Online: 48%

- **28% Medical Physicists**
  - Onsite: 53%
  - Online: 47%

- **9% Clinical Oncologists**
  - Onsite: 42%
  - Online: 58%

- **8% RTTs, RT Nurses**
  - Onsite: 45%
  - Online: 55%

- **4% Other medical specialties**
  - Onsite: 50%
  - Online: 50%

- **2% Radiobiologists**
  - Onsite: 55%
  - Online: 45%

- **1.5% Computer scientists**
  - Onsite: 56%
  - Online: 44%

- **1% Dosimetrists**
  - Onsite: 40%
  - Online: 40%

- **0.34% Medical oncologists**
  - Onsite: 57%
  - Online: 43%

- **0.1% Quality managers**
  - Online: 100%
PARTICIPATION

Top 10 countries

The Netherlands: 422
- Onsite: 260
- Online: 162

Germany: 330
- Onsite: 162
- Online: 168

Spain: 320
- Onsite: 263
- Online: 57

UK: 312
- Onsite: 112
- Online: 200

France: 299
- Onsite: 192
- Online: 107

USA: 276
- Onsite: 138
- Online: 138

Belgium: 231
- Onsite: 171
- Online: 60

Switzerland: 226
- Onsite: 156
- Online: 71

Italy: 223
- Onsite: 124
- Online: 99

Sweden: 201
- Onsite: 146
- Online: 55

Evolution of participation to the ESTRO congress

- ESTRO 35: 5,284
  - Participants and Visitors: 4,665
  - Company Delegates: 1,219

- ESTRO 36: 5,860
  - Participants and Visitors: 4,333
  - Company Delegates: 1,527

- ESTRO 37: 6,211
  - Participants and Visitors: 4,856
  - Company Delegates: 1,355

- ESTRO 38: 6,633
  - Participants and Visitors: 5,157
  - Company Delegates: 1,526

- ESTRO 2020: 3,047
  - Participants and Visitors: 2,529
  - Company Delegates: 518

- ESTRO 2021: 4,120
  - Participants and Visitors: 3,708
  - Company Delegates: 412

EXHIBITION

3,708 Sqm

- Main Exhibition: 3,690
- Start-up Corner: 18

60 Onsite Exhibitors
- Exhibitors: 53
- Start-ups: 3
- Community Pavillon: 4

69 Online Exhibitors
- Exhibitors: 60
- Start-ups: 3
- Community Pavillon: 6
2. Joint and collaboration events 2021

2.1 World Congress of Brachytherapy (WCB)
6-8 May 2021 | online

The Groupe Européen de Curiethérapie-European SocieTy for Radiotherapy and Oncology (GEC-ESTRO) developed the WCB scientific programme in close collaboration with the American Brachytherapy Society (ABS) and supported by the Australasian Brachytherapy Group (ABG), the Asociación Ibero Latinoamericana de Terapia Radiante Oncológica (ALATRO), the Canadian Brachytherapy Group (CBG), the Federation of Asian Organizations for Radiation Oncology (FARO) and the Indian Brachytherapy Society (IBS).

The Congress offered state-of-the-art teaching lectures, symposia and debates around the topics of physics, prostate, gynaecology, breast, gastrointestinal, head and neck, eye/orbit, and skin, and health economics.
Top 10 countries

- Spain: 53 delegates
- The Netherlands: 52
- UK: 42
- Germany: 38
- Canada: 36
- USA: 36
- Australia: 21
- Belgium: 19
- Sweden: 18
- Switzerland: 12

Breakdown per Specialty

- 89.59% RO Specialty
  - 45.38% Radiation Oncologists
  - 23.97% Medical Physicists
  - 5.89% Clinical Oncologists
  - 4.52% RTTs, RT nurses
  - 0.79% Computer Scientist
  - 0.79% Medical Oncologist
  - 0.59% Dosimetrist
  - 7.66% Other
- 4.72% Other Medical Specialities
- 3.73% RO Industry - Corporate
- 1.96% Other Non-Medical Specialities
The 13th European Multidisciplinary Congress on Urological Cancers (EMUC 21) placed a specific emphasis on the importance of multi-sectoral approach in the treatment of genitourinary (GU) malignancies. The EMUC 21 scientific programme highlighted the most recent developments in the prevention, diagnosis and best practices in the management of GU cancers.

2.2 European Multidisciplinary Congress on Urological Cancers (EMUC)

25-28 November 2021 | Athens, Greece - Jointly organised by EAU, ESMO and ESTRO

- Jointly organised by EAU, ESMO and ESTRO

Greece: 175 delegates
Spain: 114
Belgium: 76
The Netherlands: 76
Portugal: 53
UK: 48
Germany: 46
Italy: 43
Russia: 31
France: 25
Organised by the ESMO and IASLC with ESTRO, European Society of Thoracic Surgeons (ESTS) and the European Thoracic Oncology Platform (ETOP) as partners.

The ELCC is a collaboration of the most important multidisciplinary societies that represent thoracic oncology specialists, working together to advance science, disseminate education and improve the practice of lung-cancer specialists worldwide.

Medical oncologists, radiation oncologists, thoracic surgeons, respiratory physicians/pneumologists, interventional radiologists and pathologists all benefit from its comprehensive and stimulating programme.

2.3 European Lung Cancer Conference (ELCC 2021)
25-27 March 2021 | Online

3,717 Participants
118 Countries represented
255 Abstracts
218 accepted
37 rejected or withdrawn

Record-breaking congress: +99.8% compared to 2019

91.4% Delegates
3.9% Sponsors
3.1% Faculty
1.6% Press

Top 10 countries
USA: 8.4%
Spain: 7%
UK: 6.3%
Italy: 5.9%
Switzerland: 5.4%
Germany: 4%
Romania: 4%
China: 3.6%
Portugal: 3.4%
France: 3.1%

Top 5 professions
84.1% Clinicians
8.2% Basic scientists
3% Pharmacists
1.5% Other healthcare professionals
1.2% Medical students
2% Other

Breakdown of participants
The Physics Workshop, organised by the ESTRO Physics Committee, aims to facilitate scientific and professional networking opportunities between the ESTRO physics membership, physicists working in other areas, and with developers in companies.

Five tracks ran in parallel at the 5th Physics Workshop:

- Clinical translation of CT innovations in Radiation Oncology: Opportunities, requirements and standardisation
- Commissioning and quality assurance for deformable image registration in radiotherapy
- Harmonisation and standardisation in SBRT planning
- Mining the radiotherapy dose: exploring dose-response patterns in radiation therapy
- Physics aspects of FLASH.

Top 5 countries

- UK: 22 Participants
- Germany: 16
- Italy: 15
- Belgium: 13
- USA: 13
3.2 GEC-ESTRO Workshop 2021
9-10 February 2022 | ONLINE

Initially planned to be held in Rotterdam in November 2021, the GEC-ESTRO Workshop had to be postponed due to the travel restrictions linked to the Covid-19 and was held online on 9-10 February 2022.

GEC-ESTRO annual workshop is now a hallmark platform for networking with the seven GEC-ESTRO working groups. The 7th edition covered multiple aspects of brachytherapy, with each working group covering a site-specific aspect of the speciality.

The programme involved plenary sessions. Additionally included was one company satellite symposium plus two sessions at which two companies were given the possibility to present some of their brachytherapy projects in development.

728 Delegates

Top 5 countries
- Portugal: 88 participants
- UK: 82
- The Netherlands: 71
- Spain: 30
- Romania: 29

Top 5 disciplines
- 30.9% Radiation oncologist
- 20% Medical physicist
- 10% RTT (Radiation Therapist), RT nurse
- 8.2% Basic scientists
- 5.9% Clinical oncologist
- 10.3% Other
1. The Green Journal

Editor-in-chief: Michael Bauman (Heidelberg, Germany)

Radiotherapy & Oncology, known as the Green Journal, is the flagship publication in ESTRO’s family of journals. It covers all aspects of Radiation Oncology, publishing themed issues, editorials and correspondence, as well as original research and review articles.

Article transfer service to CIRO, PhiRO and TipsRO

For manuscripts not selected for publication in Radiotherapy & Oncology, authors may be provided with the option of having their manuscript transferred to an ESTRO Open Access publication.

Submitted papers

- Manuscript submissions:
  - 1,755 submitted abstracts:
    - 408 Accepted papers
    - 1,326 Rejected
    - 30 Withdrawn or removed

- Submitted articles by region:
  - 32.4% Europe
  - 17.6% North and central America
  - 45.4% Asia
  - 2.2% Oceania
  - 1.7% South America
  - 0.7% Africa

Evolution of the number of articles submitted:

- 2018: 1,528
- 2019: 1,613
- 2020: 2,175
- 2021: 1,755
**ACCEPTED PAPERS**

Top 10 countries of accepted papers

- USA: 75
- The Netherlands: 62
- China: 47
- Germany: 32
- UK: 28
- Canada: 22
- Italy: 15
- Belgium: 15
- France: 14
- Denmark: 13

The region and country are derived by affiliation of the corresponding author.

---

**IMPACT FACTOR**

Evolution impact factor trend

- 2012: 4.520
- 2013: 4.857
- 2014: 4.363
- 2015: 4.817
- 2016: 4.328
- 2017: 4.942
- 2018: 5.252
- 2019: 4.856
- 2020: 6.280

2021 impact factor not known yet.
MOST CITED ARTICLES IN 2021
Published between 2019 and 2021

92 citations in 2021
Treatment of a first patient with FLASH-radiotherapy
। 2019

71 citations in 2021
Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document
। 2020

69 citations in 2021
Clinical translation of FLASH radiotherapy: Why and how?
। 2019

These papers contribute to the 2021 Impact Factor.

MOST DOWNLOADED ARTICLES IN 2021
Regardless of publication date

27,494 downloads in 2021
The tubarial salivary glands: A potential new organ at risk for radiotherapy
। 2021

18,249 downloads in 2021
Delineation of the neck node levels for head and neck tumors: A 2013 update. DAHANCA, EORTC, HKNPCSG, NCIC CTG, NCRI, RT0G, TROG consensus guidelines
Grégoire, V., Ang, K., Budach, W., Grau, C., Hamoir, M., Langendijk, J., Lee, A., Le, Q., Maingon, P., Nutting, C., O’Sullivan, B., Porceddu, S., Lengele, B.
। 2014

11,067 downloads in 2021
ESTRO consensus guideline on target volume delineation for elective radiation therapy of early-stage breast cancer
। 2015

TOP ARTICLES BY SOCIAL MEDIA ATTENTION *

186,986 social media attention in 2021
The tubarial salivary glands: A potential new organ at risk for radiotherapy
। 2021

185,891 social media attention 2021
Quality assurance standards drive improvements in the profile of radiation therapy departments participating in trials of the EORTC Radiation Oncology Group
Grant W., Hurkmans C.W., Poortmans P.M., Maingon P., Monti A.F., Van Os M.J.H., Weber D.C.
। 2014

185,786 social media attention 2021
Spacers in radiotherapy treatment of prostate cancer: Is reduction of toxicity cost-effective?
। 2015

*Social Media Attention is captured as a lifetime metric showing cumulative views, shares, likes comments etc. from publication up to YTD, regardless of publication date.
2. Open access journals

All members of ESTRO are eligible for a discounted fee to publish a paper in any of the three open access journals. The fees vary depending on whether the manuscript is a full-length original research article, a short-format case report, technical note or short communication. All correspondence commenting on previously published work is published free of charge.
2.1 Clinical & Translational Radiation Oncology (ctRO)

Co-editors: Pierre Blanchard (Villejuif, France) and Daniel Zips (Berlin, Germany)

Clinical & Translational Radiation Oncology features research on all aspects of clinical and translational radiation oncology, particularly new developments in experimental radiobiology, clinical interventions and treatments. This includes imaging and biomarker studies with a clinical endpoint, as well as research results from data sciences, epidemiology and oncopolicy.

SUBMITTED PAPERS

Evolution of the number of articles submitted

<table>
<thead>
<tr>
<th>Year</th>
<th>Articles</th>
</tr>
</thead>
<tbody>
<tr>
<td>2017</td>
<td>76</td>
</tr>
<tr>
<td>2018</td>
<td>94</td>
</tr>
<tr>
<td>2019</td>
<td>145</td>
</tr>
<tr>
<td>2020</td>
<td>200</td>
</tr>
<tr>
<td>2021</td>
<td>184</td>
</tr>
</tbody>
</table>

Accepted papers by region

- 41.3% Europe
- 33.2% North and central America
- 20.7% Asia
- 4.3% Oceania
- 0.5% Africa

45% REJECTION RATE

ACCEPTED PAPERS

Top 5 countries of accepted papers

- USA: 27
- The Netherlands: 21
- Canada: 12
- France: 9
- UK: 9

Breakdown of accepted papers per publication type

- 110 accepted papers:
  - Case report: 7
  - Correspondence: 2
  - Full length article: 85
  - Review article: 8
  - Short communication: 8
MOST CITED ARTICLES IN 2021
Published between 2019 and 2021

96 citations in 2021
Adaptive radiotherapy: The Elekta Unity MR-Linac concept
2019

52 citations in 2021
Technical design and concept of a 0.35 T MR-Linac
Kluter S.
2019

41 citations in 2021
COVID-19: Global radiation oncology's targeted response for pandemic preparedness
2020

These papers contribute to the 2021 Impact Factor.

MOST DOWNLOADED ARTICLES IN 2021
Regardless of publication date

5,190 downloads in 2021
Adaptive radiotherapy: The Elekta Unity MR-Linac concept
2019

3,979 downloads in 2021
Technical design and concept of a 0.35 T MR-Linac
Kluter S.
2019

3,826 downloads in 2021
Dose constraints for whole breast radiation therapy based on the quality assessment of treatment plans in the randomised Danish breast cancer group (DBCG) HYPO trial
2021

TOP ARTICLES BY SOCIAL MEDIA ATTENTION *

525 social media attention in 2021
COVID-19: Global radiation oncology’s targeted response for pandemic preparedness
2020

341 social media attention in 2021
Board-certified specialty training program in radiation oncology in a war-torn country: Challenges, solutions and outcomes
2019

133 social media attention in 2021
Dose to penile bulb is not associated with erectile dysfunction 18 months post radiotherapy: A secondary analysis of a randomized trial
2018

*Social Media Attention is captured as a lifetime metric showing cumulative views, shares, likes comments etc. from publication up to YTD, regardless of publication date.
2.2 Physics & Imaging in Radiation Oncology (phiRO)

Physics & Imaging in Radiation Oncology focuses on medical physics and imaging in radiation oncology. The journal publishes original research articles, reviews, technical notes, short communications and correspondence.

Submitted papers

Evolution of the number of articles submitted

Accepted papers

Top 5 countries of accepted papers

The Netherlands: 17
USA: 10
Sweden: 7
UK: 7
Germany: 6

Breakdown of accepted papers per publication type

73 accepted papers:
- Full length article: 58
- Review article: 2
- Short communications: 13

35% REJECTION RATE
MOST CITED ARTICLES IN 2021
Published between 2019 and 2021

34 citations in 2021
Clinical implementation of magnetic resonance imaging guided adaptive radiotherapy for localized prostate cancer
Tetar S.U., Bruynzeel A.M.E., Lagerwaard F.J., Slotman B.J., Bohoudi O., Palacios M.A. ▪ 2019

19 citations in 2021
Evaluation of measures for assessing time-saving of automatic organ-at-risk segmentation in radiotherapy

17 citations in 2021
A single neural network for cone-beam computed tomography-based radiotherapy of head-and-neck, lung and breast cancer

These papers contribute to the 2021 Impact Factor.

MOST DOWNLOADED ARTICLES IN 2021
Regardless of publication date

3,100 downloads in 2021
Relationship between dosimetric leaf gap and dose calculation errors for high definition multi-leaf collimators in radiotherapy
Kim, J., Han, J., Hsia, A., Li, S., Xu, Z., Ryu, S. ▪ 2018

3,076 downloads in 2021
Machine learning applications in radiation oncology
Field, M., Hardcastle, N., Jameson, M., Aherne, N., Holloway, L. ▪ 2021

3,057 downloads in 2021
Clinical implementation of artificial intelligence-driven cone-beam computed tomography-guided online adaptive radiotherapy in the pelvic region

TOP ARTICLES BY SOCIAL MEDIA ATTENTION *

308 social media attention in 2021
Global availability of dosimetry audits in radiotherapy: The IAEA dosimetry audit networks database
Izewska J., Lechner W., Wesolowska P. ▪ 2018

84 social media attention in 2021
Multi-center evaluation of dose conformity in stereotactic body radiotherapy
Lee J., Dean C., Patel R., Webster G., Eaton D.J. ▪ 2019

33 social media attention in 2021
Machine learning applications in radiation oncology
Field, M., Hardcastle, N., Jameson, M., Aherne, N., Holloway, L. ▪ 2021

*Social Media Attention is captured as a lifetime metric showing cumulative views, shares, likes comments etc. from publication up to YTD, regardless of publication date.
Technical Innovations & Patient Support in Radiation Oncology (tipsRO)

Editor: Michelle Leech (Dublin, Ireland)

Technical Innovations & Patient Support in Radiation Oncology offers radiation therapists, nurses and allied health professionals a forum for the publication of original research, case reports, practice development and health evaluation articles, reviews, short communications, technical notes and correspondence on topics including treatment planning and workflows, treatment delivery and verification, supportive care, psycho-oncology, education and training.

SUBMITTED PAPERS

Evolution of the number of articles submitted

Accepted articles by region

64.6% Europe
16.9% North and central America
10.8% Asia
7.7% Oceania

26% REJECTION RATE

USA: 8
Sweden: 5
UK: 5
India: 4
The Netherlands: 4

44 accepted papers:
- Correspondence: 3
- Full length article: 31
- Short communications: 10
MOST CITED ARTICLES IN 2021
Published between 2019 and 2021

10 citations in 2021
On-line adaptive MR guided radiotherapy for locally advanced pancreatic cancer: Clinical and dosimetric considerations
Placidi L., Romano A., Chiloio G., Cusumano D., Boldrini L., Cellini F., Mattiucci G.C., Valentini V.
📆 2020

8 citations in 2021
Advanced practice: An ESTRO RTTC position paper
Duffton A., Devlin L., Tsang Y., Mast M., Leech M.
📆 2019

8 citations in 2021
Sarcopenia in cancer: Risking more than muscle loss
Anjanappa M., Corden M., Green A., Roberts D., Hoskin P., McWilliam A., Choudhury A.
📆 2020

These papers contribute to the 2021 Impact Factor.

MOST DOWNLOADED ARTICLES IN 2021
Regardless of publication date

3,873 downloads in 2021
Side effects in breast implants related to radiotherapy in breast cancer reconstructive surgery
Winkel de Faria Castro Fleury, E., Jasmin Huanca Bernal, K., Lucena Miranda Madeiro, A., Luis Cervera Ocana, W., Carlos Vendramini Fleury, J., Caobianco, L.
📆 2021

3,833 downloads in 2021
Sarcopenia in cancer: Risking more than muscle loss
Anjanappa M., Corden M., Green A., Roberts D., Hoskin P., McWilliam A., Choudhury A.
📆 2020

2,377 downloads in 2021
ESTRO ACROP guidelines for positioning, immobilisation and position verification of head and neck patients for radiation therapists
Leech, M., Coffey, M., Mast, M., Moura, F., Osztavics, A., Pasini, D., Vaandering, A.
📆 2017

TOP ARTICLES BY SOCIAL MEDIA ATTENTION *

339 social media attention in 2021
Analysis of dose using CBCT and synthetic CT during head and neck radiotherapy: A single centre feasibility study
📆 2020

91 social media attention in 2021
Advanced practice: An ESTRO RTTC position paper
Duffton A., Devlin L., Tsang Y., Mast M., Leech M.
📆 2019

74 social media attention in 2021
Side effects in breast implants related to radiotherapy in breast cancer reconstructive surgery
Winkel de Faria Castro Fleury, E., Jasmin Huanca Bernal, K., Lucena Miranda Madeiro, A., Luis Cervera Ocana, W., Carlos Vendramini Fleury, J., Caobianco, L.
📆 2021

*Social Media Attention is captured as a lifetime metric showing cumulative views, shares, likes comments etc. from publication up to YTD, regardless of publication date.
2.4 ESTRO Newsletter

The ESTRO newsletter provides a more informal space for members to read about the latest developments in the radiation oncology field and its community.

In each issue expert editors, selected from the membership, curate contents for themed disciplinary ‘Corners’ or report on specific topics. The newsletter typically includes information on the latest advances in research and practice, interviews with key opinion leaders, conference findings, a selection of research papers and paper reviews.

Find all the articles on the ESTRO Website: www.estro.org/About/Newsroom/Newsletter

Top five most read corners in 2021 (online)

1. Read it before your patients
2. Physics
3. Brachy
4. Young ESTRO
5. RTT corner
RESEARCH

ESTRO is committed to supporting research relevant to its members and to the Radiation Oncology community. The scope of ESTRO involvement varies with the research topic, the type of research activity, and the level of support requested.

On the next pages are explanations of research activities in which ESTRO was involved in 2021.

E²-RADIATE - EORTC-ESTRO Radiation infrastructure for Europe programme

E²-RADIatE (EORTC 1811 study) is a platform that collects real-world data through prospective data registries in radiotherapy. A collaboration between the European Organisation for Research and Treatment of Cancer (EORTC) and ESTRO, it aims to be a pan-European infrastructure and a more efficient framework across the field of Radiation Oncology to generate robust data in cancer treatment and to further develop and integrate the discipline into therapeutic strategies.

E²-RADIatE comprises three innovative cohorts:

- **OligoCare** (EORTC 1822-RP) is a pragmatic observational cohort study to evaluate radical radiotherapy for patients with oligometastatic disease. The main objective is to identify patient, tumour, diagnostic and treatment characteristics impacting overall survival.

- **ParticleCare** (EORTC 1833-RP) has as objective to provide continuing evidence of the benefit of particle therapy at a European level for the most common tumour types. Almost all particle therapy facilities in Europe will participate in this cohort.

- **ReCare** (EORTC 2011-RP) will gather clinical evidence on the safety and efficacy of high-dose re-irradiation and to guide clinical practice and inform on consistent standards of care.
As of 14th December 2020, 20 sites in six countries were activated for E²-RADIatE and opened for enrolment in OligoCare. Another 30 - 40 sites in 13 countries are planned for activation by the first half of next year. If you are interested in participating, please visit the website for more information.

project.eortc.org/e2-radiate/platform

The OligoCare cohort of E²-RADIatE continues to recruit very well enrolling the 1000th patient at the end of 2021. The first preliminary results from this cohort were presented at ESTRO 2021 with the poster “Real-world patient and treatment characteristics of oligometastatic disease – initial results of the ESTRO & EORTC E²-RADIatE OligoCare cohort” (Presentation Number: PD-0740).

An “ESTRO EORTC OligoCare Workshop: E2-RADIatE OligoCare cohort - An observational basket study evaluating radical radiotherapy for Oligo-Metastatic Cancer Patients” was hosted virtually on 30 June and 1 July 2021.

The first day of workshop consisted of presentations on oligometastatic disease by experts in the field. The second day focused on the OligoCare cohort with successful participation from the principal investigators of the recruiting centres. Presentation recordings are available on the ESTRO website for ESTRO members via following link: www.estro.org/Library.
European Particle Therapy Network (EPTN)

EPTN, a task force of ESTRO, was created to promote clinical and research collaboration between the rapidly increasing members of European particle therapy (PT) centres and to ensure particle therapy became integrated in the overall Radiation Oncology community.

Since the last annual meeting held online in 2020, the EPTN has been further involved in the European Commission’s Steering Group on Health Promotion, Disease Prevention and Management of Non-Communicable Diseases through its sub-group on proton therapy. This sub-group is co-chaired by representatives of the Directorate-General for Health and Food Safety (DG SANTE) and the European Investment Bank (EIB). At a sub-group meeting in January 2021, it was confirmed that possible investment in proton therapy had been put on hold until the need for/benefit of proton therapy was confirmed. On the other hand, the European Investment Bank (EIB) is willing to support a new research project on proton therapy with the European Commission and the European Atomic Energy Community (Euratom).

The seventh European Particle Therapy Network (EPTN) virtual workshop took place in a virtual setting on 22 October 2021 and was attended by 48 participants.

During the workshop, the results of two surveys that have been conducted among members of the particle therapeutics community to assess the impact of Covid-19, were presented. The results seem to indicate that the community has responded robustly to the pandemic challenge, with only minor implications for daily activities, referrals and the fraction schedules that have been used.

Continued activity in the working groups has resulted in the publication of several papers and scientific reports:


1. Highlights of the 2021 activities of the EPTN Working Parties

WP1: Clinical
WP1 has two tasks, the first of which is to produce a white paper on methodological issues that are encountered in clinical studies for the validation of the added value of proton therapy, either using classical approaches (phase I, II, III studies) or alternative methods. To this purpose, a first virtual meeting will be organised in the first quarter of 2022 with representatives of the EPTN centres and experts in the field of statistics in epidemiology.

WP2: Dose assessment, quality assurance, dummy runs, technology inventory
As of October 2021, 38 participants were contributing to WP2, from 27 centres based in 12 countries. WP2 has decided to organise two workshops each year rather than one. One would be online to discuss updates regarding the running of activities and organisational aspects; and one would be in-person on a specific theme. The thematic WP2 workshop took place on 6 May 2021 as an online event on the topic of ultra-high-dose-rate (FLASH) dosimetry. The workshop was well received with over 60 participants. The next thematic WP2 workshop will be on the TRS-398 Code of Practice in early 2022.

WP3: Education
The focal activity for WP3 is to provide training and educational opportunities for Radiation Oncology professionals who are already involved in, or are at least approaching, the field of particle therapy. The specific form of training events that the WP would like to trial is short workshops (two to three day), open to a small number of participants (30 people maximum), dedicated to a specific disease site, to discuss the specific issues of particle therapy in a way that is relevant to clinicians, medical physicists and radiotherapists.

The first workshop will be on brain and base-of-skull tumours and will be hosted by the Paul Scherrer Institute (PSI) in Switzerland in 2022.

If this first workshop test is successful, the WP plan is to design a series of periodic events, in which other disease sites will be discussed at other locations in Europe. These workshops are meant to complement the ESTRO school course on clinical particle therapy, which remains the main educational ESTRO event on particle therapy and which represents an excellent starting point for those who are approaching the field of particles.

WP4: Image guidance in particle therapy
Image guidance for particle therapy (IGPT) is essential to guarantee accurate dose delivery and to minimise the effects of range uncertainties that are related to patient misalignment and anatomical changes that occur during the course of therapy. Multiple imaging modalities for IGPT are available and routinely used clinically. However, due to a lack of standardised procedures for IGPT, most centres have developed their own strategies, which are based on their available infrastructure, technical implementation and dose delivery methods. The need to collaborate among centres has been recognised and centres have set two primary goals: 1) to develop clinical consensus guidelines for IGPT; and 2) to pursue research projects to optimise existing IGPT techniques and to develop new ones.
As a first step in the development of clinical consensus guidelines, it is the aim of WP4 to gain insight into the current clinical practice parameters of IGPT in European particle therapy centres via multiple detailed surveys. Preliminary results from the summary response data will be shared between the WP4 sub-working groups.

A first IGPT research project that involves multi-centre evaluation of the inter- and intra-fraction patient-positioning accuracy for brain tumour patients undergoing particle therapy has been initiated. The study aims and endpoints are currently being defined within the working party. A call to participate in this study will be launched in early 2022.

Due to the Covid-19 pandemic, the annual WP4 workshop was moved to 2022.

WP5: Treatment planning systems in particle therapy
Treatment planning systems are essential to ensure that particle therapy is accurate and effective, and they are an important part of the particle therapy workflow. The aim of this working party is to review and provide recommendations on numerous aspects of the treatment planning process.

WP5 was initially split into groups to consider six main subjects:

1. Collective TPS specifications
2. Planning standards and case solutions (together with Italy, Poland, Austria, Czech Republic and Sweden (IPACS)
3. TPS commissioning and validation
4. Alternatives to patient-specific verifications
5. Computed tomography/Hounsfield unit (CT/HU) calibration
6. Robustness analysis.

Two new subject groups have now been added:
- The role of linear energy transfer (LET)
- 4D planning.

Several new directions for WP5 are being considered, including the formation of a new task group on adaptive processes and workflows, the drawing up of a more precise definition of the role of automatic treatment planning, performance of reviews of optimisation objectives and algorithms, and consideration of the role and validation of deformable registration algorithms.

WP6: Radiobiology and relative biological effectiveness
WP6 and the coordinator of working party 9 of the INSPIRE project on mathematical modelling and simulation, conducted a survey on current clinical practice regarding relative biological effectiveness (RBE) in European particle therapy centres. The questions in the survey were aimed at formation of an overview on whether RBE and LET were taken into account in clinical practice in European particle therapy centres and if so, how this was done in practical terms. All European centres were invited to take part in the survey, and all centres responded. The first data from the survey were presented at ESTRO 2021. The main findings were that almost all centres considered a variable proton RBE, particularly for organs at risk, but did not necessarily apply it. Most of these centres stated that they chose beam angles carefully to avoid an increase in risk. To move forward, they called for more clinical proton RBE data and tools to calculate LET and RBE during treatment planning.

WP7: Health economy
This working party aims to focus on cost accounting first and costs that, in a second step, can be used to support an economic evaluation of health. Ideally, an approach should be followed that enables alignment with the work already performed in the Health Economics in Radiation
2. Collaborative EU projects

**Proton versus photon therapy for oesophageal cancer (PROTECT)**

PROTECT compares the clinical outcomes of proton therapy and state-of-the-art photon radiotherapy for locally advanced oesophageal cancer. In the PROTECT trial, the potential benefits of proton therapy will be tested in a trimodality treatment of radiotherapy, chemotherapy and surgery.

A total of 19 public and industry partners across Europe are joining forces in this ambitious collaborative clinical research project. The aim is to set new standards for the clinical use of proton radiotherapy.

The partnership behind the PROTECT trial has engaged 13 recruiting units, 38 institutions, 12 particle therapy facilities, 25 sub-sites and two major particle therapy equipment manufacturers. The project has received funding from the Innovative Medicines Initiative (IMI), the European Federation of Pharmaceutical Industries and Associations (EFPIA), and the companies Ion Beam Applications (IBA) and Varian, a Siemens Healthineers Company. It is the first public-private partnership in which funding from the industry has been matched by funding from the EU.

The funding was approved in July 2021. The project, which comprises 11 working groups, is expected to take six years.

**Real-time adaptive particle therapy of cancer (RAPTOR)**

RAPTOR is an EU horizon 2020-funded programme. It was initially headed by the University of Groningen and subsequently by PSI. The project brings together 13 beneficiaries and 15 partner organisations. The aim is to bring adaptive particle therapy to the clinic.

The project plan comprises an adaptation loop (imaging, verification, intervention), training and dissemination working groups. All PhD students have been recruited and, as an initial training session, the first meeting of the RAPTOR school took place on 13-17 December 2021.

**Heavy ion therapy research integration-plus (HITRiplus) project**

HITRiplus (hitriplus.eu) is a four-year research project funded by the European Commission under the horizon 2020 programme (H2020-INFRAIA-2020-1). The project, which started on 1 April 2021, aims to integrate and propel forward biophysics and medical research on...
cancer treatment that uses heavy-ion beams while jointly developing its sophisticated instruments. Through transnational access, HITRIplus gives a unique opportunity to European hospitals and oncology institutes to gain access to and share clinical expertise in heavy-ion therapy through the creation of links among clinicians who refer patients to hadron-therapy facilities. The project aims to attract universities, research centres and hospitals to use the beam time and research facilities of the heavy-ion centres. Its networks will structure and foster clinical and pre-clinical research on heavy-ion therapy. Joint research activities are developing new accelerator and beam-delivery technologies to extend the reach of the present generation of centres and to define a new European reference design, at lower cost and dimensions, to make ion therapy for cancer more accessible and to open new markets to European industry.

For more information on the activities of the EPTN please visit: www.estro.org/Science/Activities/EPTN

The QuADRANT project is led by the European Society of Radiology (ESR) together with the European Association of Nuclear Medicine (EANM) and ESTRO as consortium partners. QuADRANT aims to promote constant improvement in quality and safety of radiology, radiotherapy, and nuclear medicine through the implementation of clinical audit as part of Member States’ healthcare systems.

Three ESTRO experts are involved in all the QuADRANT work packages.

Following the first QuADRANT workshop, held in December 2020, a report on the outcomes of the workshop was published in 2021. The report to the European Commission on the workshop, as well as all workshop slides, can be viewed here: QuADRANT Workshop Report.

In 2021, the project main survey was conducted with the goal of reviewing the status of implementation of clinical audit in several European countries and identifying and reporting on good practices and available guidance for clinical audit at national, European and international level. Additionally, interviews were conducted with experts in the field of clinical audit. The results of the QuADRANT main survey and expert interviews have been analysed and a report submitted to the European Commission. The final “Recommendations & Guidance Document” is planned for publication in late 2022.
GUIDELINES

The following guidelines were developed under the auspices of the Advisory Committee on Radiation Oncology Practice (ACROP) in 2021.

- ESTRO-ACROP recommendations on the clinical implementation of MR-Linac in radiation oncology
  www.thegreenjournal.com/article/S0167-8140(21)06162-4/fulltext

- Salvage stereotactic body radiotherapy (SBRT) for intraprostatic relapse after prostate cancer radiotherapy: An ESTRO ACROP Delphi consensus
  pubmed.ncbi.nlm.nih.gov/33965893/

- IBS-GEC ESTRO-ABS recommendations for CT based contouring in image guided adaptive brachytherapy for cervical cancer
  www.thegreenjournal.com/article/S0167-8140(21)06248-4/fulltext

- ESTRO ACROP guidelines for the delineation of lymph nodal areas in upper gastrointestinal malignancies
  www.thegreenjournal.com/article/S0167-8140(21)06721-9/fulltext#secst075

- ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma
  www.thegreenjournal.com/article/S0167-8140(20)31188-9/fulltext

ACROP endorsed guidelines in 2021

- Radiation Therapy for Treatment of Soft Tissue Sarcoma in Adults: Executive Summary of an ASTRO Clinical Practice Guideline
  www.practicalradonc.org/article/S1879-8500(21)00118-1/fulltext

- External Beam Radiation Therapy for Primary Liver Cancers: An ASTRO Clinical Practice Guideline
  www.practicalradonc.org/article/S1879-8500(21)00233-2/fulltext
ESTRO SCHOOL
The ESTRO School’s mission is to:
- improve, professionalise and harmonise knowledge and practice in radiation oncology and associated professions in Europe and beyond.

To this end, the School:
- offers a wide range of live educational activities and online educational resources that enable professionals worldwide to acquire the top-most updated knowledge, skills and competencies in their daily practice.
- supports the implementation of the European Core Curricula with education and training programmes that target both young and senior Radiation Oncology professionals to deliver high-quality treatment and care to cancer patients.

In 2021, the ESTRO School demonstrated adaptability in a context still marked by travel and gathering restrictions due to the Covid-19, and pursued its efforts to allow the community to keep track with education and knowledge.

For the second year consecutively, most of the teaching courses were held online. Several new formats have been developed to enrich the educational programme and make it accessible to everyone:

- Pre-recorded lectures
- Live online lectures
- Modules spreading the programme over several weeks, or condensed in a few days
- Live broadcasting of some of the courses with the faculty members teaching live at the ESTRO office (using the ONLINE PLUS format)
1. TEACHING COURSES

1.1 A RICH PALETTE ON OFFER

The portfolio of live teaching courses includes basic and more advanced courses that are targeted at the various Radiation Oncology professions.

- Radiotherapy treatment planning and delivery: external beam and brachytherapy
- Multimodal cancer treatment, in general and also site-specific treatment
- Imaging
- Best practice
- Research
- Biological aspects of Radiation Oncology

The topics cover the main areas of Radiation Oncology and multidisciplinary cancer treatment courses on:

1.2 2021 AT A GLANCE

Breakdown participants per continent
Courses online and onsite

- 74% Europe
- 4% Americas
- 2% South-East Asia
- 7% Eastern Mediterranean
- 10% Western Pacific
- 2% Africa
- 1% Unknown

Top 10 countries
Courses online and onsite

- The Netherlands: 151
- UK: 146
- Romania: 129
- Australia: 115
- Iran: 107
- Belgium: 106
- Switzerland: 92
- Serbia: 92
- Germany: 73
- France: 68

- 74% Europe
- 4% Americas
- 2% South-East Asia
- 7% Eastern Mediterranean
- 10% Western Pacific
- 2% Africa
- 1% Unknown
Top 3 most attended courses

- 270 participants
  Implementation and Practice of Image-guided Stereotactic Body Radiotherapy
- 204 participants
  Image-Guided and Adaptive Radiotherapy
- 151 participants
  Basic Clinical Radiobiology

2 Onsite courses

21 Online courses

Growth in the number of courses and participants over the years

1,988 Participants
1,364 Members
624 Non-Members

Courses
Participants


Implementation and Practice of Image-guided Stereotactic Body Radiotherapy
204 participants

Image-Guided and Adaptive Radiotherapy
151 participants

Basic Clinical Radiobiology
270 participants
1.3  PRE MEETING COURSES

ESTRO offers one-day teaching courses that occur on the day before the start of its annual congress. Five pre-meeting courses took place onsite in Madrid on 27 August 2021 at the occasion of ESTRO 21.

Number of participants per pre-meeting course

- **CLINICAL** - Artificial intelligence for clinicians: 33 participants
- **INTERDISCIPLINARY** - Intra-operative radiation therapy: 48 participants
- **PHYSICS** - The evolving role of medical physicists in clinical trials: 33 participants
- **RADIOBIOLOGY** - Radiobiology of novel irradiation modalities: 25 participants
- **RTT** - Clinical implementation of surface guided radiotherapy (SGRT): 10 participants
2. E-LEARNING

2.1 Training in delineation

An accurate and precise anatomical contouring of target volume and OaRs* is of utmost importance in radiotherapy. FALCON**, ESTRO’s contouring programme, allows Radiation Oncology professionals to improve their contouring skills.

In using the FALCON EduCase software, trainees can compare their individual contours with those made by delineation experts and visualise the ESTRO international guidelines.

FALCON is integrated into the whole portfolio of the educational ESTRO activities:

- Live courses
- Workshops at ESTRO meetings
- Online virtual workshops
- Support services for clinical trials and development of guidelines
- Delineation workshops for other societies (IAEA, national societies or other societies active in the field of oncology)

* Organs at Risk
**Fellowship in Anatomic deLineation and CONtourings
### 2.2 Online delineation workshops

**Top 3 countries**
- Australia: 50
- UK: 45
- Germany: 39

**Geographic distribution of participants**
at online blended FALCON workshops

- 63% Europe
- 8% Americas
- 2% South-East Asia
- 4% Eastern Mediterranean
- 18% Western Pacific
- 2% Africa
- 3% Unknown

**Evolution of number of participants**
at online delineation workshops

<table>
<thead>
<tr>
<th>Year</th>
<th>Participants</th>
<th>Members</th>
<th>Non-Members</th>
</tr>
</thead>
<tbody>
<tr>
<td>2015</td>
<td>106</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2016</td>
<td>70</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2017</td>
<td>8</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2018</td>
<td>288</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2019</td>
<td>274</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2020</td>
<td>13</td>
<td>396</td>
<td></td>
</tr>
<tr>
<td>2021</td>
<td>14</td>
<td>418</td>
<td></td>
</tr>
</tbody>
</table>

**Participants**
- 418
- 349 Members
- 69 Non-Members

**Online delineation workshops**
- 14 Workshops

**Participants**
- 349
- 69 Members
- 69 Non-Members
In addition to the pre-meeting courses, ESTRO offers hands-on delineation workshops in the framework of the annual congress.

Number of participants per contouring workshop

- Central nervous system: 21
- Organs at risk in head and neck: 16
- Small cell lung cancer: 15
- Breast cancer - Boost and PBI TV contouring: 9
- Breast cancer - TV contouring after mastectomy and reconstruction: 10

71 Participants
5 Contouring workshops held online prior to ESTRO 21
3. CORE CURRICULUM

ESTRO and EFOMP (European Federation of Organisations for Medical Physics) have been working on the third revision of the Core Curriculum (CC) for education and training of Medical Physics Experts (MPE) in radiotherapy (RT).

3.1 Aim

The aim of the revision of the CC is to improve the standard and quality of training of MPE and hence contribute to further harmonisation of the level of MPE across Europe.

3.2 Process

The working group active in the CC revision process included 27 MPE from 19 countries who were representatives from ESTRO and EFOMP education councils, young physicists/trainees and national societies representatives.

3.3 A competency-based education

The revision of the CC was based on:
- The latest European Commission guidelines on MPE (RP-174)
- EFOMP policy statement 12.1
- CanMEDS methodology, reinforcing the concept of competency-based education.
Specific competences were then highlighted as a priority: expertise, collaboration, contribution and awareness.

3.4 Content

The revised CC is a proposal for a 4-year training programme offering a complete description of knowledge, skills and competences required to be licensed as an MPE.

The most recent advances in RT medical physics were defined as to be part of the third CC:
- MR-guided RT
- Automation
- Complex quantitative data analysis
- Personalised treatments
- FLASH RT.

It was highlighted that more emphasis was needed on:
- Quality management
- Particle therapy
- Science and innovation.

The revised core curriculum has been published on the Green Journal:
www.thegreenjournal.com/article/S0167-8140(22)00097-4/fulltext
With more than 7,000 Radiation Oncology professionals from across the world, the ESTRO membership is the heart of our Society.

ESTRO contributes to the day-to-day practice and career advancement of oncology professionals through the dissemination of the latest trends in practice, research findings and knowledge.
MEMBERSHIP

ESTRO offers several levels of membership, with benefits tailored to the needs of each member and their degree of involvement within the Society.

The full range of ESTRO membership benefits includes:

- Belonging to a community of more than 7,000 Radiation Oncology professionals
- Reduced fees for attending ESTRO congresses, workshops and courses
- Networking opportunities
- Online access to scientific material, including events webcasts and delineation cases
- Subscription to Radiotherapy & Oncology, the Society’s journal, and reduced member fees for publishing in the ESTRO open access journals
- Eligibility for grants, awards, ESTRO faculties and governance positions
- Voting rights at the ESTRO General Assembly
1. Profile of ESTRO Members

Breakdown of ESTRO members by speciality

- 47.6% Radiation oncologists
- 19.6% Medical physicists
- 10.3% RTTs - nurses - dosimetrists
- 8% Clinical oncologists
- 1% Radiobiologists
- 13.5% Other medical and non-medical specialities

Geographical distribution

- 72.3% Europe
- 9.7% Western Pacific
- 8.1% Americas
- 2.4% South-East Asia
- 1.2% Eastern Mediterranean
- 1% Africa
- 5.3% Unknown

The ESTRO community extends far beyond these professional radiation oncology disciplines, taking in a wide range of other professions.

This includes professionals from:
- other medical fields, such as surgeons, radiologists, medical oncologists, gynaecologists and urologists
- and non-medical fields, such as public affairs specialists.

Top 10 countries

- The Netherlands: 11.3%
- Italy: 6.6%
- Germany: 6.2%
- UK: 6%
- Belgium: 5.6%
- Australia: 5.6%
- Switzerland: 5.3%
- Spain: 4.4%
- France: 3.6%
- USA: 3.5%
Evolution of membership

In 2021, the number of ESTRO members decreased by 5%, a drop that one can attribute to the Covid-19 pandemic.

However, the slight impact despite the global difficult context shows the strong commitment of the ESTRO members who seem to find in the membership programme an opportunity to leverage their professional development.
2. A wide range of membership categories

- **INDIVIDUAL MEMBERS (4,065)**
  - 36% FULL (2,607)
    - 34.8% Active (2,517)
    - 1.1% Supporting ambassador (80)
    - 0.1% Emeritus (10)
  - 20.2% ASSOCIATE (1,458)
    - 14.1% Affiliate (1,022)
    - 6% In-Training (428)
    - 0.1% Honorary (8)
  - 20.1% INSTITUTIONAL MEMBERS (1,452)
    - 50 Institutes

- **JOINT MEMBERS (1,041)**
  - 8.1% Joint (86)
  - 6.3% Joint In-Training (455)

- **RTT ALLIANCE MEMBERS (475)**
  - 23 National societies

- **CORPORATE MEMBERS (196)**
  - 36 Companies

- **14.4%**
  - 36% FULL (2,607)
  - 20.2% ASSOCIATE (1,458)
  - 20.1% INSTITUTIONAL MEMBERS (1,452)
  - 56.2% INDIVIDUAL MEMBERS (4,065)

- **50 Institutes**
- **23 National societies**
- **36 Companies**
- **10 Joint (86)**
- **455 Joint In-Training (455)**
3. Membership categories under the spotlight

1. Institutional membership

The institutional membership is designed for centres aiming to support their oncology teams in their professional development. It also fosters interdisciplinarity and multidisciplinarity within the departments.

With this category, centres can purchase packages of individual memberships on behalf of their employees, at attractive conditions.

Centres also benefit from an increased visibility with:

- A dedicated institutional webpage on the ESTRO website
- A complimentary exhibitor booth at the Communities Pavilion during the annual congress
- Free online job postings
- An “ESTRO institutional member” logo.

50
Institutes in total
(see annex for list)

1,452
Employees supported through this membership category

1
New institutional member in 2021

New institutional member in 2021:
Cancer Diseases Hospital, Zambia

2. Supporting ambassador membership

This membership category is reserved for professionals in the field of Radiation Oncology who are strongly committed to supporting the ESTRO activities in the enhancement of the radiotherapy community.

111
Individuals signed up as supporting ambassadors.
3. In-Training members and members under 40 years old

It is essential for ESTRO to invest and connect with the next generation of healthcare professionals and decision-makers.

To this end, ESTRO consolidates its collaboration with European societies representing the new generation of Radiation Oncology professionals and encourages them to join the Society.

ESTRO In-Training members are professionals in the field of Radiation Oncology who are in training or full-time PhD, have obtained their diploma within the last 10 years and are under 40 years old.

3,179 Young members in the Society
(younger than 40 years old)

4. Joint membership

This category can be granted to individual members who benefit from a joint membership agreement, signed on a case-by-case basis between ESTRO and a non-European society or a young national society active in the field of Radiation Oncology.

5. Corporate members

The ESTRO Corporate Membership offers many opportunities to engage with the community of Radiation Oncology specialists and decision-makers. With the Gold membership, corporate partners are invited to sit at the ESTRO Advisory Corporate Council.

Corporate members in 2021

36 corporate members:
- 20 gold members
- 16 regular members

Breakdown of In-Training members

1,174 In-Training members:
- 428 individual In-Training
- 311 institutional In-Training
- 455 Joint In-Training

Illustrations of the involvement of the new generation of professionals in the ESTRO community

The Young Corner
Dedicated section in the ESTRO newsletter with news from young national societies and young members sharing their experience through meetings, travel grant reports, etc.

The Young Track
All-day session held during ESTRO’s annual congress, which focuses specifically on topics of interest to young professionals.
Memoranda of understanding (MoUs) on science, education and membership are key agreements that enable ESTRO to establish new collaborations and nurture existing ones with other societies in the field of oncology.

In 2021, ESTRO signed MoUs with the following national and international societies:
- European Organisation for Research and Treatment of Cancer (EORTC)
- European Federation of Organisations for Medical Physics (EFOMP)
- European Society of Radiology (ESR)
- American Society for Radiation Oncology (ASTRO)
- Australasian College of Physical Scientists and Engineers in Medicine (ACPSEM).

Additional MoUs are being drafted and renewed in 2022.

The objective of the RTT Alliance, initiated by ESTRO a few years ago, is to strengthen the collaboration with national societies representing RTTs, at both European and international level.

In 2021, two additional national societies joined the RTT Alliance:
- Association of Medical Radiology Engineers in the Federation of Bosnia and Herzegovina (UIMR FBiH)
- French Society of Radiologic Technologists (AFPPE).

Full list available in the Annex.
The ESTRO Cancer Foundation (ECF) continues its efforts to foster the outreach of radiotherapy at the European level, especially by implementing UpLung, a project initiated in 2020, and by launching in 2021 the Value Based HealthCare (VBHC) project. Both initiatives aim at improving the access of patients to high-quality radiotherapy treatment.
The Value Based HealthCare (VBHC) project

In 2021, ESTRO and the ECF launched VBHC, a new project run in partnership with Varian and Elekta, aiming to optimise patient access to high-value radiotherapy.

Over the past decades, cancer care expenditures have seen an unprecedented increase, following the ever-growing number of innovations made available in all aspects of cancer treatment 1. Rising budgets call for a careful appraisal of both outcomes and costs of new interventions being introduced in clinical practice. Whereas traditional cost-effectiveness or cost-utility tools tend to focus on whether an intervention meets a pre-defined threshold for cost per outcome, VBHC has been defined as ‘the health outcomes (that matter most to patients) achieved per dollar spent’ 2.

The intent of VBHC is to provide a tool for assessing the value of radiotherapy innovations, in view of their clinical implementation and equitable access within a sustainable healthcare system.

The VBHC project will provide a framework to define value in Radiation Oncology by:
- Defining and categorising innovations in radiation oncology
- Defining endpoints needed for policy making in Radiation Oncology
- Linking endpoints and interventions with the evidence needed
- Providing a value framework, publications and communication collaterals (policy papers, key messages) for the radiotherapy community to adopt and the oncology community to acknowledge it, creating potential impact on health technology assessment (HTA) of Radiation Oncology innovations.

The VBHC project work is embedded in the HERO (Health Economics of Radiation Oncology) project of ESTRO, launched in 2012 with the ambition to generate a model and knowledge base for health economics and health services research in radiation oncology 3.

In order to advance in the development of scientific outputs to support the development of a value-framework for Radiation Oncology in the context of the HERO project, VBHC will be run in scientific collaboration with the University of Ghent.

The project will run for three years and will conclude by providing a framework for VBHC in radiation oncology with policy implications.

Links to publications related to the project:

Value-based radiotherapy: A new chapter of the ESTRO-HERO project

Innovation, value and reimbursement in radiation and complex surgical oncology: Time to rethink

REFERENCES
Use of radiotherapy for Lung cancer in Europe - UpLung

UpLung, an ESTRO-HERO project run in partnership with AstraZeneca, was officially launched in November 2020 addressing the challenges of the uptake of radiotherapy for lung cancer patients in Europe.

Based on previous ESTRO-HERO expertise and cooperation with the Collaboration for Cancer Outcomes Research and Evaluation (CCORE), this project has seen progress during 2021 with the development of updated lung cancer decision trees in Work Package 1, necessary in defining the optimal use of radiotherapy for lung cancer.

That is, how many patients diagnosed with lung cancer would require radiotherapy during the course of their disease, relying on evidence-based recommendations. Also, a systematic review of the literature on patterns of care for lung cancer treatment has been successfully completed to compare optimal use of radiotherapy in this tumour site with the actual use.

Starting from the concept of the CCORE decision-analytic trees, the work package first consisted of developing a set of new decision trees, adapted to the latest evidence-based care on lung cancer radiotherapy by stage, accounting for comorbidities, and guided by a review of the available guidelines and specific literature. These are currently being populated with new epidemiological data on lung cancer (incidence from Globocan; stage data from dedicated cancer registries). For the latter, the project has to initially team up with the Belgian Cancer Registry. After the analysis of this granular data input, an extrapolation will be performed towards radiotherapy utilisation at the European level, based on Globocan data.

Next to this quantitative analysis, a qualitative evaluation will be performed to deepen the understanding of the barriers and facilitators to closing the gap in utilisation and access.
1. Treasurer’s report for 2021

Our Society as a whole is going through some difficult times, forcing us to anticipate and adapt constantly. Suddenly, the concept “VUCA-world” is no longer a theoretical concept to be contemplated, yet a harsh reality. To appreciate the annual report of 2021, I would like to commend the ESTRO office for showing great resilience and flexibility in coping with the uncertainties and constant changes that were thrown in our path. It’s fair to say that we managed to get out of the COVID-19 storm with minimal damage, and to quote Nietzsche: “Was mich nicht umbringt, macht mich starker”*. As it is not over yet, we are not in a position to make drastic changes, however, we have learned a lot from this period and the main message will be to keep the efficient ways of working that emerged from 2019-2021 and merge them with those activities that made ESTRO strong in the past (to give but one example: blending telework, when useful, with face-to-face meetings to connect and discuss).

The new ESTRO offices are a nice illustration where a pleasant and inviting environment is created to stimulate networking and collaborations in small groups, whilst the absence of personalised desks mirrors the concept of working at home for administrative tasks and individual projects, optimising economy and work-life balance at the same time.

Let’s return to 2020 in some more detail: the auditors provided an unqualified opinion and the audited figures showed a total net result of -€371k and -€420k excluding and including financial and extraordinary charges respectively. While the total revenue generated by the ESTRO activities exceeded €4.93M the total of expenditures represented an amount of €5.31M.

At the time of writing this report, the figures for 2021 are being audited and the final result will be presented for approval at the next general assembly in May 2022. The year 2021 was yet again challenging for ESTRO’s activities and its stakeholders. As the financial situation remained unpredictable, we were forced to carefully monitor operational costs in order to reduce pressure on cash whilst maintaining a solid scientific/educational program and continuation of services. With the help and efforts from all of you we were able to adapt activities and formats successfully. The cash flow in 2021 was more solid compared to 2020, and we anticipate a slight positive result, contrary to the intermediary scenarios as they were presented in May and October 2021. Revenues and expenses at the end of 2021 are estimated at €6.02M and €5.94M respectively, with an expected total net result of €44k (including the financial and extraordinary results). The total revenue for the blended ESTRO 2021 annual meeting was above €3.36M. The revenue generated by the memberships represented €766k in 2021; with respectively €410k from the individual membership, €220k from the corporate membership and €136k from the institutional membership.

From a cumulative balance perspective, ESTRO will recover in 2022. However, we should keep in mind that we are not yet out of the storm, and cumulative balance and cashflow pressure are two separate and independent tiers. Therefore, the message from the previous annual report remains strong: ESTRO needs to build up its reserves in order to create a healthy buffer to face calamities such as the COVID-19 pandemic, without however, loosing focus on re-investing revenue into services to its members. Diversification of our revenue sources will be key. The
governance task force has picked-up its activities again, and it was decided to initiate a budget cycle of three years aligning all of the Society’s projects.

The ESTRO Portfolio (a defensive, Social Responsible (ethical) Investment profile, managing the cash reserves) was of course impacted by the pandemic and will be by the war in Ukraine. The total reserve showed a capital of €2.31M euro at the end of 2021, which was not too bad considering the general economic situation.

In closing, I would like to thank you all for your commitment to ESTRO and our industry partners for the continuous support. All things considered, together we seem to be managing this crisis quite well. As always, please feel free to contact me anytime with questions or concerns regarding ESTRO’s financial situation, and of course, I look forward to meeting you all, in person, at our annual meeting in Copenhagen.

Think pink, and warm regards,

Dirk Verellen
ESTRO Treasurer

*What does not kill me, makes me stronger

The figures presented in this report were approved at the ESTRO general assembly on 14 April 2021.

In 2021, operating revenues rose to almost €4.934 million, led by registrations at meetings and courses, and exhibition subscriptions.

The financial income constituted an amount of €10,000 while the financial charges, including bank charges and credit card commissions, represented €59,000.

With operating expenses of €5.305 million, the net impact of income and expenditure is a net result of -€420,000.
2. ESTRO Audited Accounts 2020
Everything in KEUR except mentioned otherwise

Revenue
- Registrations (meetings, courses, ...) 1,409
- Exhibition 1,401
- Advertisement/Sponsoring 169
- Membership 361
- Corporate Memb. 196
- Elsevier Royalties/Comm. 741
- Other Revenues 677
TOTAL 4,934

Expenditure
- Venue 379
- Tech. Equipment 795
- Promo. & Comm. 22
- Catering 40
- Scient. Educ. Prog & Commit. 325
- Governance (Commit & Council) 48
- Other Activity Costs 246
- Payrol charges 2,396
- General & Administration 398
- Elsevier charges 175
- General IT (incl. website) 93
- Communication/Marketing 388
TOTAL 5,305

Financial result
- Financial Incomes 10
- Bank & Credit card charges -50
- Other Financial charges -9
TOTAL -49

Net Result (Net Profit) -420
Consolidated Result 2008 - 2021

-1000000
-800000
-600000
-400000
-200000
0
200000
400000
600000
800000
1000000

2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
1. Governance & Constituent Bodies

**Board of directors**
- President-Elect: Ben Slotman - Amsterdam, The Netherlands
- President: Ben Slotman - Amsterdam, The Netherlands
- Executive council:
  - Non-voting director – Education Council Director: Jesper Eriksen - Aarhus, Denmark
  - Non-voting director – Green Journal Editor-in-Chief: Michelle Leech - Dublin, Ireland
- Board Member:
  - Nuria Jornet - Barcelona, Spain
  - Matthias Guckenberger - Zurich, Switzerland
  - Marc Vooijs - Maastricht, The Netherlands
  - Kari Tanderup - Aarhus, Denmark
  - Esther Troost - Dresden, Germany
  - Ben Heijmen - Rotterdam, The Netherlands
- Past-President:
  - Umberto Ricardi - Turin, Italy
  - Umberto Ricardi - Turin, Italy
  - Anna Kirby - London, UK

**Nominating council**
- President: Ben Slotman - Amsterdam, The Netherlands
- President-Elect: Anna Kirby - London, UK
- Non-Presidet:
  - Ben Slotman - Amsterdam, The Netherlands

**Scientific council**
- President: Ben Slotman - Amsterdam, The Netherlands
- Chair:
  - Anna Kirby - London, UK
  - Umberto Ricardi - Turin, Italy
  - Michael Baumann - Heidelberg, Germany
  - Michael Baumann - Heidelberg, Germany
  - Peter Hoskin - Northwood, UK

**Executive council**
- President: Ben Slotman - Amsterdam, The Netherlands
- Non-Presidet:
  - Anna Kirby - London, UK

**Board of directors**
- President: Ben Slotman - Amsterdam, The Netherlands
- President-Elect: Anna Kirby - London, UK
- Non-Presidet:
  - Ben Slotman - Amsterdam, The Netherlands
- Past-President:
  - Umberto Ricardi - Turin, Italy
  - Umberto Ricardi - Turin, Italy
- Treasurer: Dirk Verellen - Antwerp, Belgium
- Past-President:
  - Umberto Ricardi - Turin, Italy
  - Umberto Ricardi - Turin, Italy

**CEO**
- Alessandro Cortese – Brussels, Belgium

**Treasurer**
- Dirk Verellen - Antwerp, Belgium

**Past-President**
- Umberto Ricardi - Turin, Italy

**President**
- Ben Slotman - Amsterdam, The Netherlands

**Nominating council**
- President: Ben Slotman - Amsterdam, The Netherlands
- President-Elect: Anna Kirby - London, UK
- Non-Presidet:
  - Ben Slotman - Amsterdam, The Netherlands

**Scientific council**
- President: Ben Slotman - Amsterdam, The Netherlands
- Chair:
  - Anna Kirby - London, UK
  - Umberto Ricardi - Turin, Italy
  - Michael Baumann - Heidelberg, Germany
  - Michael Baumann - Heidelberg, Germany
  - Peter Hoskin - Northwood, UK

**Executive council**
- President: Ben Slotman - Amsterdam, The Netherlands
- Non-Presidet:
  - Anna Kirby - London, UK
2. Staff

- **CEO**
  - Alessandro Cortese

- **Education**
  - Viviane Van Egten 
    - Education Manager
  - Laura La Porta 
    - Servic Manager Education
  - Simone De la Maree 
    - Governance & Education Project Manager
  - Agré Delmar 
    - Committees & Education Project Manager
  - Karolina Kowalska 
    - Committees & Education Project Manager
  - Andrea Colaresi 
    - Committees & Education Project Manager
  - Mikael Palma 
    - Servic Project Manager
  - Alessandra Nappa 
    - Project Manager

- **Science**
  - Eralda Azizaj 
    - Senior Manager Science
  - Jessica Pledge 
    - Scientific Programme Manager

- **Public affairs & partnerships**
  - Chiara Gasparotto 
    - Director of Policy & Partnerships
  - Valerie Cremades 
    - Membership & Partnerships Manager

- **Events**
  - Agostino Baricco 
    - Procurement and Events Manager
  - Jean-Paul Bliau 
    - Congress Manager

- **Corporate relationships**
  - Hande Van Gennip 
    - Exhibition Project Manager

- **Society affairs & executive office**
  - Amélie Leboucq 
    - Senior Society Affairs & Policy Manager
  - Evelyn Chromweerde 
    - Manager Society Affairs & Research Projects
  - Laura Corso Turnarelli 
    - Marketing & Communication Coordinator

- **Registration & administration**
  - Sigrid Jacobs-Peeters 
    - ECF Programme Supervisor
  - Rebecca Hansmann 
    - ECF Programme & Office Administrator
  - Claire Thomas 
    - ECF Programme Administrator
  - Céline Dechamps 
    - ECF Programme Administrator

- **Finance**
  - Ahmad Ponkari 
    - Finance Manager
  - Gunjan Luevy 
    - Accounting Coordinator
  - Dina Ardiana 
    - Finance & HR Coordinator

- **Human Resources**
  - Nathalie Croops 
    - Senior HR Manager

- **IT**
  - Michael Bisland 
    - IT Development Manager
  - Benjamin Cerny 
    - IT Support Officer

- **ESTRO Cancer Foundation - ECF**
  - Anta Seel 
    - ECF Programme Manager

- **Consultants**
  - Mieke Akkers 
    - Education Project Manager
  - David Maggertis 
    - Graphic Designer
  - Cécile Hamon-Villard 
    - Strategic communication

3. Corporate Members

- **Gold corporate members**
  - ACCURA
  - BOSTON SCIENTIFIC
  - CHICD RADIOThERAPY
  - DHLTA INSTRUMENT AB
  - Ion Beam Applications
  - MIN SOFTWARE INC
  - NEOMEDIC
  - ORBIT INDUSTRIES
  - PHILIPS
  - QERK
  - RaySearch Laboratories AB (Publ)
  - S.I.T. - SORINNA IORT TECHNOLOGIES S.P.A
  - SIEMENS HEALTHCARE GMBH
  - SUN NUCLEAR CORPORATION
  - VARIO MEDICAL SYSTEMS INTERNATIONAL AG
  - VIEWRAY

- **Corporate members**
  - AQUILAB
  - AstraZeneca PLC
  - BRAINLAB
  - CANON MEDICAL SYSTEMS EUROPE
  - Carl Zeiss Meditec AG
  - C-ROAD POSITIONING AB
  - ECKERT & ZIEGLER BEBIG GMBH
  - KLAUS MEDICAL & EQUIPMENT CO. LTD
  - LVZ MEDICAL TECHNOLOGIES
  - MACROMEDICS BV
  - MEYSON MEDICAL SYSTEMS
  - MICROPOS MEDICAL
  - OPAACA GMBH
  - PMB-ALCEN
  - PTW Freiburg
  - RAD TECHNOLOGY
  - RADFORMATION
  - STANDARD WAGING
  - VISION RT LTD
4. Joint members

Joint Radiation Oncology National Societies and Other Oncology Societies

- Associazione Italiana di Radioterapia Oncologica Giovani (Young ARD - AIRO GIOVANI)
- Belgian Society for Radiation Oncology (BSRT)
- Israeli Society for Clinical Oncology and Radiotherapy (ISCRRT)
- Royal Australian and New Zealand College of Radiologists (RANZCR)
- Spanish Society for Radiation Oncology (SEOR)
- Tunisian Society of Radiation Oncology (STOR)
- Young Romanian Radiation Oncologists Group (YRROG)

- American Association of Physics in Medicine (AAPM)
- Association of Medical Physicists of India (AMPI)
- Australasian College of Physical Scientists and Engineers in Medicine (ACPSiM)
- Canadian Association of Radiation Oncology (CARO)
- European Society of Gynaecological Oncology (ESGO)
- International Association for the Study of Lung Cancer (IASLC)
- Iranian Society of Clinical Oncology (ISCO)
- Japanese Society for Radiation Oncology (JASTRO)
- Sociedad Chilena de Radioterapia (SOCHIRA)
- Sociedade Brasileira de Radioterapia (SBRTr)
- South East Asian Radiation Oncology Group (SEAROG)

5. RTT Alliance

European RTT Alliance Members

- Austria: Society of Radiological Technology Austria
- Belgium: Association Francophone des Techniciens en Radiothérapie
- Belgium: Vereniging Verpleegkundigen Radiotherapie en Oncologie
- Bosnia and Herzegovina: Association of Medical Radiology Engineers in the Federation of Bosnia and Herzegovina
- Bulgaria: Bulgarian Society of Radiation Therapy Technicians
- Croatia: Croatian Association of Radiation Technologists
- Denmark: Radiograf Rådet
- Estonia: Estonian Society of Radiographers
- France: French Society of Radiologic Technologists
- Georgia: Association of Georgia Radiation Treatment Therapists
- Ireland: Irish Institute of Radiography and Radiation Therapy
- Italy: Italian Association of Radiation Therapists and Medical Physics Technologists
- Macedonia: Association and Chamber of Radiological Technologists of Macedonia
- Malta: Society of Medical Radiographers
- Poland: Polish Society of Electroradiology
- Portugal: Portuguese Association of Radiation Therapists
- Serbia: Serbian Society of Radiation Therapy Technicians
- Spain: Spanish Society for Radiotherapy and Oncology
- Switzerland: Swiss Association of Radiographers
- Turkey: Society of Radiation Therapy Technologists

Global RTT Alliance Members

- Brazil: Associação de Técnicos em Terapias de Irradiação
- Chile: Sociedad Chilena de Radioterapia Oncológica
- India: Association of Radiation Therapy Technologists
## 6. Institutional Members

<table>
<thead>
<tr>
<th>Country</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Belgium</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>AZ Turnhout</td>
</tr>
<tr>
<td></td>
<td>CHU Liège</td>
</tr>
<tr>
<td></td>
<td>GZa Ziekenhuizen, Sint Augustinus - Iridium</td>
</tr>
<tr>
<td></td>
<td>Kankerrenetwerk Antwerpen</td>
</tr>
<tr>
<td></td>
<td>Institut Jules Bordet</td>
</tr>
<tr>
<td></td>
<td>Université Hospital Gaethtalberg (U2 Leuven)</td>
</tr>
<tr>
<td></td>
<td>Universite Ziekenhuis Brussel</td>
</tr>
<tr>
<td><strong>Czech Republic</strong></td>
<td>University Hospital Hradec Kralove</td>
</tr>
<tr>
<td><strong>Denmark</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Aalborg University Hospital</td>
</tr>
<tr>
<td></td>
<td>Odense University Hospital</td>
</tr>
<tr>
<td><strong>Estonia</strong></td>
<td>North Estonian Regional Hospital Cancer Center</td>
</tr>
<tr>
<td><strong>France</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Institut de Radioprotection et de Sécurité Nucléaire</td>
</tr>
<tr>
<td></td>
<td>Centre Oscar Lambret</td>
</tr>
<tr>
<td></td>
<td>Centre Léon Bérard</td>
</tr>
<tr>
<td></td>
<td>Institut Curie</td>
</tr>
<tr>
<td></td>
<td>Institut Gustave Roussy</td>
</tr>
<tr>
<td><strong>Germany</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Gemeinschaftspraxis fuer Strahlentherapie</td>
</tr>
<tr>
<td></td>
<td>Singen-Friedrichshafen</td>
</tr>
<tr>
<td></td>
<td>Klinikum Maria Hilf</td>
</tr>
<tr>
<td></td>
<td>Klinikum Rhechts Der Isar, TU Munich</td>
</tr>
<tr>
<td><strong>Hungary</strong></td>
<td>University of Debrecen Clinic of Oncology</td>
</tr>
<tr>
<td><strong>Italy</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>ASU Careggi - University of Florence</td>
</tr>
<tr>
<td></td>
<td>Fondazione IRCCS Instituto Nazionale Tumor</td>
</tr>
<tr>
<td></td>
<td>Humanitas Cancer Center</td>
</tr>
<tr>
<td></td>
<td>Fondazione CNAD</td>
</tr>
<tr>
<td><strong>The Netherlands</strong></td>
<td>Leiden University Medical Center</td>
</tr>
<tr>
<td></td>
<td>MAASTROI - Netherlands Cancer Institute</td>
</tr>
<tr>
<td></td>
<td>Radboud University Medical Center</td>
</tr>
<tr>
<td></td>
<td>Radiotherapiegrup (Delft)</td>
</tr>
<tr>
<td></td>
<td>The Institute of Cancer Research</td>
</tr>
<tr>
<td></td>
<td>UMC Utrecht</td>
</tr>
<tr>
<td></td>
<td>VU University Medical Center</td>
</tr>
<tr>
<td><strong>Poland</strong></td>
<td>Greater Poland Cancer Center</td>
</tr>
<tr>
<td><strong>Portugal</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Joaquim Chaves Clinica Medica Ambulatorio</td>
</tr>
<tr>
<td><strong>Romania</strong></td>
<td>Regional Institute of Oncology</td>
</tr>
<tr>
<td><strong>Russia</strong></td>
<td>Oneclosp</td>
</tr>
<tr>
<td><strong>Spain</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Institut IKOR</td>
</tr>
<tr>
<td></td>
<td>Fundacion Instituto de Investigacion Biomedica de Bellvitge (IDIBELL)</td>
</tr>
<tr>
<td><strong>Sweden</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Karolinska University Hospital</td>
</tr>
<tr>
<td></td>
<td>Sodersjukhuset AB</td>
</tr>
<tr>
<td><strong>Switzerland</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Centre Hospitalier Universitaire Vaudois</td>
</tr>
<tr>
<td></td>
<td>Kantonsspital Graubunden</td>
</tr>
<tr>
<td></td>
<td>Kantonsspital St. Gallen</td>
</tr>
<tr>
<td></td>
<td>Luzerner Kantonsspital</td>
</tr>
<tr>
<td></td>
<td>University Hospital Zürich</td>
</tr>
<tr>
<td><strong>UK</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Velindre University NHS Trust</td>
</tr>
<tr>
<td></td>
<td>Western General Hospital, Edinburgh Cancer Centre</td>
</tr>
<tr>
<td><strong>Zambia</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Cancer Diseases Hospital</td>
</tr>
</tbody>
</table>
Clinical and Translational Radiation Oncology

Editors
Piero Blanchard, MD, PhD – Gustave Roussy, Villejuif, France
Daniel Zips, MD – University of Tübingen, Tübingen, Germany

Associate Editors
Jovana Kazmierska, MD, PhD – Greater Poland Cancer Centre, Poznan, Poland
Hina Saeed, MD – Medical College of Wisconsin, Milwaukee, Wisconsin, USA

Editorial Board Members
Mirtsev Arena Praal, MD, PhD – Sint Jan University Hospital of Brussel, Brussels, Belgium
Alexandre Berzin, MD, MSc – Princess Margaret Hospital Cancer Centre, Toronto, Canada
Jean-Emmanuel Bibault, MD, MSc, PhD – Hospital Cancer Centre, Toronto, Canada
Alejandro Berlin, MD, MSc – Princess Margaret Hospital Cancer Centre, Toronto, Canada
Meritxell Arenas Prat, MD PhD – Sant Joan De Deu – Hospital, Barcelona, Spain

Editor-in-Chief
Ludwig Maruy, MSc, PhD – Aarhus University

Editor
Michelle Leech, MSc, BSc, The University of Dublin Trinity College, Dublin, Ireland

Technical Innovations and Patient Support in Radiation Oncology

Editor
Nigel Anderson, PhD – Peter MacCallum Cancer Centre, Melbourne, Australia

Editorial Board Members
Anna Fabbri, MD, MSc – The University of Melbourne
Daniela Fornari, MD, PhD – The University of Melbourne

Physics and Imaging in Radiation Oncology

Editor-in-Chief
Ludwig Maruy, MSc, PhD – Aarhus University

Editorial Board Members
Jan Busink, MD, PhD – Radboudumc, Nijmegen, The Netherlands
Claudia Fornaro, PhD – Vito-Mazzafera University Medical Centreplusl, Mazzarri, The Netherlands

Published by Editions Science

Copyright © 2023 MDPI AG

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without the prior written permission of the publisher.

Clinical and Translational Radiation Oncology

Editors
Piero Blanchard, MD, PhD – Gustave Roussy, Villejuif, France
Daniel Zips, MD – University of Tübingen, Tübingen, Germany

Associate Editors
Jovana Kazmierska, MD, PhD – Greater Poland Cancer Centre, Poznan, Poland
Hina Saeed, MD – Medical College of Wisconsin, Milwaukee, Wisconsin, USA

Editorial Board Members
Mirtsev Arena Praal, MD, PhD – Sint Jan University Hospital of Brussel, Brussels, Belgium
Alexandre Berzin, MD, MSc – Princess Margaret Hospital Cancer Centre, Toronto, Canada
Jean-Emmanuel Bibault, MD, MSc, PhD – Hospital Cancer Centre, Toronto, Canada
Alejandro Berlin, MD, MSc – Princess Margaret Hospital Cancer Centre, Toronto, Canada
Meritxell Arenas Prat, MD PhD – Sant Joan De Deu – Hospital, Barcelona, Spain

Editor-in-Chief
Ludwig Maruy, MSc, PhD – Aarhus University

Editor
Michelle Leech, MSc, BSc, The University of Dublin Trinity College, Dublin, Ireland

Technical Innovations and Patient Support in Radiation Oncology

Editor
Nigel Anderson, PhD – Peter MacCallum Cancer Centre, Melbourne, Australia

Editorial Board Members
Anna Fabbri, MD, MSc – The University of Melbourne
Daniela Fornari, MD, PhD – The University of Melbourne

Physics and Imaging in Radiation Oncology

Editor-in-Chief
Ludwig Maruy, MSc, PhD – Aarhus University

Editorial Board Members
Jan Busink, MD, PhD – Radboudumc, Nijmegen, The Netherlands
Claudia Fornaro, PhD – Vito-Mazzafera University Medical Centreplusl, Mazzarri, The Netherlands
8. Awards

**Lifetime achievement**
- Arthur Sun Myint (UK)
- Felipe Calvo (ES)
- Krzysztof Bujko (PL)

**ESTRO Award Lectures**
- Emmanuel Van der Schueren Award
  - Jasper Graus Eriksen (DK)
  - ESTRO Education: What did we learn from COVID-19?
- Jans Overgaard Legacy Award
  - Hans Langendijk (NL)
  - Towards evidence-based radiation oncology
- Regaud award
  - John Fandos (UK)
  - Hypoxia and the biology of breast cancer and some other things
- Donal Hollywood Award
  - Brita Singers Sørensen (DK)
  - In vivo validation and tissue sparing factor for acute damage of pencil beam scanning proton FLASH
- Klass Bruur Award
  - Yoelitza Liemans (BE)
  - Value-based radiotherapy: turning evidence into practice

**Honorary Chember award lectures**
- Joao Fernandes (ST)
  - Multidisciplinary cancer care: adding value in times of change
- Denis Lacombe (BE)
  - Multidisciplinary head and neck cancer research: Can we make it better than just the sum of its parts?
- Nataliia Suchowska (UA)
  - Targeting the Physics, but missing the Biology
- Ralph Wechherla (USA)
  - Radiotherapy and (Neuro)oncology: Combinations: the hype and the hope

**Honorary Physicist**
- Csak Stephan (HU)
  - Honorary award
- Marie Curie Medal
  - Monica Martinez (USA)

**ESTRO Elekta Brachytherapy award**
- Michele Cuss (NL)
  - Automated multi-criteria treatment planning for adaptive IMRT-RT for locally advanced cervical cancer

**GEC-ESTRO Best Junior Presentation - sponsored by Elekta Brachytherapy**
- Michael Ebeling (DE)
  - Does dose to the ureter predict for ureteral stenosis? - Analysis of 3D MRI-based brachytherapy

**Company Award**
- ESTRO Elekta Brachytherapy award
  - Michele Cuss (NL)
  - Automated multi-criteria treatment planning for adaptive IMRT-RT for locally advanced cervical cancer

**Posters**

**Best Clinical Poster award**
- Thirumal Sambam (IT)
  - Prediction of toxicity after prostate cancer RT: The value of a SNP (single nucleotide polymorphism) risk score

**Best Physics Poster Award**
- Peter Hofma (NL)
  - Real-time multi-resolution image reconstruction for MR-guided prostate radiotherapy

**Best RTT Poster Award**
- Heather Hibbert (UK)
  - An evaluation of a therapeutical radiographer’s use of “Sexual Care after Radiotherapy” clinic

**ESTRO/ITCO award - sponsored by Elekta**
- Carine deiman (DE)
  - Modulated electro-hyperthermia improves three-year survival in cervical cancer patients

**ESTRO/ITCO award - sponsored by Elekta**
- Tsvi Meir (IL)
  - Realiability of free-breathing diffusion weighted MRI for MR guided hyper- SBRT

**ESTRO/ITCO award - sponsored by Elekta**
- Yanis Antonis Chaloulakos (Greece)
  - Treatment uncertainty for ultra- vs. standard-hypofractionated breast RT based on in-vivo dosimetry

**ESTRO/ITCO award - sponsored by Elekta**
- Ylva Cunliffe (SE)
  - Treatment uncertainty for ultra- vs. standard-hypofractionated breast RT based on in-vivo dosimetry

**Read it Before Your Patients corner**
- Filippe Lambin
- Hans Kaanders
- Dirk de Breybroe

**Physics corner**
- Laura Cella
- Alan Mcwilliam
- Kathrine Røe Redalen

**Brachytherapy Corner**
- Peter Hoskin
- Bradley Peters
- Åsa Carlsson Tedgren

**RTT corner**
- Ilija Ćurić
- Isabel Lobato
- Annette Schauboe

**Ludwig Van Den Bergh Radiobiology corner**
- Bob Coppens

**ROSQ**
- Mary Coffey

**Course reports**
- Jasper Graus Eriksen
- Marie-Catherine Vozenin
- Laura La Porta
- Viviane Van Egten

**Young ESTRO corner**
- Jenny Bertholet
- Sophie Perryck

9. Newsletter

- Read it Before Your Patients corner
- Filippe Lambin
- Hans Kaanders
- Dirk de Breybroe

- Physics corner
- Laura Cella
- Alan Mcwilliam
- Kathrine Røe Redalen

- Brachytherapy Corner
- Peter Hoskin
- Bradley Peters
- Åsa Carlsson Tedgren

- RTT corner
- Ilija Ćurić
- Isabel Lobato
- Annette Schauboe

- Ludwig Van Den Bergh Radiobiology corner
- Bob Coppens

- ROSQ
- Mary Coffey

- Course reports
- Jasper Graus Eriksen
- Marie-Catherine Vozenin
- Laura La Porta
- Viviane Van Egten

- Young ESTRO corner
- Jenny Bertholet
- Sophie Perryck